We are happy to announce that our application has been approved. Our clinical study will evaluate the performance and safety of the Zolidd One ExHex dental implant compared to uncoated One ExHex dental implant in subjects with partial edentulism. Patients will be recruited during fall at our participating sites. We are eager to start!
"This is an important milestone for AddBIO and the Zolidd project. Now we can start the important clinical study that will take us to a CE-mark and commercialisation" says Ulf Sewerin, CEO of AddBIO.